Skip to main content
. 2020 May 12;14(10):330–336. doi: 10.5489/cuaj.6440

Table 2.

Subgroup analyses using biochemical progression-free survival endpoint

Subgroup Trials included Pooled effect (HR, 95% CI, p, I2)
 Margin negative (R0) ARO-96-02
EORTC-22911		 HR 0.65, 95% CI 0.49–0.85
p=0.002, I2=0%
 Margin positive (R1) ARO-96-02
EORTC-22911		 HR 0.43, 95% CI 0.35–0.52
p<0.001, I2=0%
 T2R1 ARO-96-02
FinnProstate		 HR 0.21, 95% CI 0.04–1.01
p=0.05, I2=77%
 Extracapsular extension (regardless of margin) ARO-96-02
EORTC-22911
FinnProstate		 HR 0.43, 95% CI 0.35–0.53
p<0.001, I2=0%
 Seminal vesicle invasion ARO-96-02
EORTC-22911		 HR 0.62, 95% CI 0.48–0.82
p<0.001, I2=0%
 Gleason score 6 ARO-96-02
FinnProstate		 HR 0.29, 95% CI 0.08–1.04
p=0.06, I2=64%
 Gleason score 7 ARO-96-02
FinnProstate		 HR 0.48, 95% CI 0.34–0.67,M
p<0.001, I2=0%

Note for subgroup analysis: Thompson excluded as subgroup results only provided for metastasis-free survival. CI: confidence interval; HR: hazard ratio.